Last close As at 05/08/2026
GBP1.12
▲ −1.40 (−1.23%)
Market capitalisation
GBP698m
Research: Real Estate
Target Healthcare REIT’s Q324 update shows a fifth successive quarter of positive NAV total return, with indexed rent reviews driving increased earnings and property values. Tenant profitability continues to strengthen, reflected in a high level of rent cover and rent collection. Dividends are well covered by adjusted earnings and we expect further DPS growth.
Target Healthcare REIT |
Positive momentum continued in Q3 |
Q324 update |
Real estate |
20 May 2024 |
Share price performance
Business description
Next events
Analyst
Target Healthcare REIT is a research client of Edison Investment Research Limited |
|||||||||||||||||||||||||||||||||||||||||||||
Target Healthcare REIT’s Q324 update shows a fifth successive quarter of positive NAV total return, with indexed rent reviews driving increased earnings and property values. Tenant profitability continues to strengthen, reflected in a high level of rent cover and rent collection. Dividends are well covered by adjusted earnings and we expect further DPS growth.
Year end |
Rental |
Adjusted earnings* (£m) |
Adjusted |
NAV**/ |
DPS |
P/NAV |
Yield |
06/23 |
67.7 |
37.2 |
6.0 |
104.5 |
6.18 |
0.78 |
7.5 |
06/24e |
69.1 |
37.8 |
6.1 |
109.4 |
5.71 |
0.75 |
7.0 |
06/25e |
73.3 |
38.7 |
6.2 |
113.7 |
5.84 |
0.72 |
7.1 |
06/26e |
75.7 |
39.0 |
6.3 |
118.0 |
5.96 |
0.69 |
7.3 |
Note: *Adjusted earnings exclude revaluation movements, non-cash income arising from the accounting treatment of lease incentives and guaranteed rent review uplifts and acquisition costs, and include development interest under forward fund agreements. **NAV is net tangible assets (NTA) throughout this report.
Gains in earnings and asset values
With the portfolio yield stabilising, organic rental growth is generating valuation gains as well as higher earnings and dividend cover. Q324 NAV per share increased 2.2% to 109.0p and NAV total return was 3.6% (8.3% year-to-date). Dividend cover was 1.1x in Q3 and is 1.08x year-to-date. Rent cover on mature homes remains stable, at 1.9x, the highest level since IPO in 2013, and rent collection of more than 98% is robust. Strong fee growth, increased occupancy and the easing of staff shortages continue to support tenant profitability. There are no material changes to our earnings forecasts. We expect continuing organic revenue growth from rent reviews and development completions to drive earnings growth and fully covered DPS growth through FY26. This is despite a likely increase in borrowing costs at or ahead of the November 2025 expiry of interest rate hedges.
Profitably enhancing the UK care home estate
Target operates in a structurally supported market, driven by demographics, and largely insulated from wider economic conditions. There is a strong need to expand and improve the existing care estate and in addressing this, Target has an unwavering focus on asset quality. It invests in modern, purpose-built, high-quality residential facilities, often new to market. Its homes are energy efficient and already compliant with the minimum energy efficiency standards anticipated to apply from 2030. High-quality homes appeal to residents (71% private pay across Target’s homes), and support operators in providing better, more efficient and more effective care. When let at sustainable rent levels in well-located areas, with strong supply/demand characteristics, such properties have proven to be attractive to tenants, existing and alternative, which is key to providing sustainable, long-duration, inflation-linked income.
Valuation: Attractive yield and discount to NAV
The 5.71p FY24 DPS target represents an attractive yield of 7% and we expect further growth on a fully covered basis. Meanwhile, the shares trade at a 25% discount to the March 2024 EPRA NTA per share.
Positive trends continuing
Organic rental growth is driving increased earnings, fully covered dividend growth and property valuation gains, reflected in an uplift in NAV per share. For now, Target is focused on optimising its existing portfolio and we have not assumed any acquisitions in our forecasts. If interest rates begin to decline as is expected, opportunities for accretive capital deployment may begin to emerge. Allowing for existing investment commitments, £41m of free capital was available at end-Q324.
With the H124 financial performance in line with the previously released quarterly data, and our forecasts, Q324 continued the positive trends. There is no material change to our last published forecast for FY24 and FY25 and we expect further progress in FY26.
Exhibit 1: Summary of forecasts
New forecast |
Previous forecast |
Forecast change |
|||||||
£m unless stated otherwise |
FY24e |
FY25e |
FY26e |
FY24e |
FY25e |
FY24e |
FY25e |
FY24e |
FY25e |
Cash rental income |
58.2 |
62.2 |
64.6 |
58.2 |
62.6 |
0.0 |
(0.4) |
0% |
-1% |
Credit loss allowance |
(0.6) |
(0.6) |
(0.6) |
(0.6) |
(0.6) |
(0.0) |
0.0 |
||
Expenses |
(10.5) |
(10.8) |
(11.2) |
(10.6) |
(10.9) |
0.1 |
0.1 |
-1% |
-1% |
Net finance costs |
(11.0) |
(12.2) |
(13.8) |
(10.6) |
(11.7) |
(0.3) |
(0.5) |
3% |
4% |
Development interest under forward fund agreements |
1.6 |
0.3 |
0.0 |
0.8 |
0.0 |
0.9 |
0.2 |
108% |
651% |
Adjusted earnings |
37.8 |
38.7 |
39.0 |
37.2 |
39.3 |
0.6 |
(0.6) |
2% |
-1% |
Development interest under forward fund agreements |
(1.6) |
(0.3) |
0.0 |
(0.8) |
(0.0) |
(0.9) |
(0.2) |
||
Non-cash IFRS adjustments |
10.9 |
11.1 |
11.1 |
10.8 |
11.2 |
0.1 |
(0.1) |
||
EPRA earnings |
47.1 |
49.6 |
50.1 |
47.2 |
50.5 |
(0.2) |
(0.9) |
0% |
-2% |
EPRA EPS (p) |
7.6 |
8.0 |
8.1 |
7.6 |
8.1 |
(0.0) |
(0.1) |
0% |
-2% |
Adjusted EPS (p) |
6.1 |
6.2 |
6.3 |
6.0 |
6.3 |
0.1 |
(0.1) |
2% |
-1% |
DPS declared (p) |
5.712 |
5.840 |
5.960 |
5.712 |
5.8 |
0.0 |
0.0 |
0% |
0% |
EPRA DPS cover (x) |
1.33 |
1.37 |
1.36 |
1.33 |
1.4 |
(0.0) |
(0.0) |
||
Adjusted DPS cover (x) |
1.07 |
1.07 |
1.05 |
1.05 |
1.1 |
0.0 |
(0.0) |
||
EPRA NTA per share ("NAV") (p) |
109 |
114 |
118 |
108 |
111.5 |
1.5 |
2.2 |
1% |
2% |
NAV total return |
10.2% |
9.2% |
9.0% |
8.8% |
0.1 |
0.0 |
0.0 |
||
Source: Edison Investment Research forecasts. Note: Adjusted earnings exclude revaluation movements, non-cash income arising from the accounting treatment of lease incentives and guaranteed rent review uplifts and acquisition costs, and include development interest under forward fund agreements.
Financial performance has continued to strengthen
The past five quarters have now seen a positive development in property valuations, reflecting rental uplifts as property yields have stabilised, generating capital growth alongside consistently positive dividend returns.
Q324 NAV per share increased 2.2% to 109p and including DPS paid, the NAV total return was 3.6%, taking the total return in the first nine months of FY24 to 8.3%.
Exhibit 2: NAV return has steadily increased in recent quarters
Pence per share |
Sep-22 |
Dec-22 |
Mar-23 |
Jun-23 |
Sep-23 |
Dec-23 |
Mar-24 |
||
Q123 |
Q223 |
Q323 |
Q423 |
Q124 |
Q224 |
Q324 |
9M23 |
9M24 |
|
Opening NAV per share |
112.3 |
112.1 |
103.0 |
103.4 |
104.5 |
105.6 |
106.7 |
112.3 |
104.5 |
Unrealised property revaluation gains/(losses) |
(0.1) |
(8.4) |
0.5 |
1.0 |
1.0 |
1.1 |
2.2 |
(8.0) |
4.3 |
Gain/(loss) on disposal |
0.0 |
0.0 |
0.1 |
0.0 |
0.0 |
0.0 |
0.0 |
0.1 |
0.0 |
Premium paid on interest rate swap |
0.0 |
(0.4) |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
(0.4) |
0.0 |
Movement in revenue reserve |
1.6 |
1.4 |
1.5 |
1.5 |
1.5 |
1.4 |
1.5 |
4.5 |
4.4 |
Dividend paid |
(1.7) |
(1.7) |
(1.7) |
(1.4) |
(1.4) |
(1.4) |
(1.4) |
(5.1) |
(4.2) |
Closing NAV per share |
112.1 |
103.0 |
103.4 |
104.5 |
105.6 |
106.7 |
109.0 |
103.4 |
109.0 |
Dividend return |
1.5% |
1.5% |
1.7% |
1.4% |
1.3% |
1.3% |
1.3% |
4.5% |
4.0% |
Capital return |
-0.2% |
-8.1% |
0.4% |
1.1% |
1.1% |
1.0% |
2.2% |
-7.9% |
4.3% |
NAV total return |
1.3% |
-6.6% |
2.0% |
2.4% |
2.4% |
2.4% |
3.6% |
-3.4% |
8.3% |
Source: Target Healthcare REIT data, Edison Investment Research
Organic rental growth should continue to drive earnings
In Q324, contractual rental income increased by £2.2m, or 3.7%, to £60.1m. The increase reflected annual, inflation-indexed rent reviews,1 mostly collared and capped at 2% and 4% respectively,2 and an additional £1.7m from the completion of two pre-let development properties at Dartford in Kent and Holt in Norfolk. During the current year, organic revenue growth (including interest earned on the funding extended to developments during the construction phase) is offsetting increased net finance costs. With borrowing costs now fixed on 89% of drawn debt, we expect organic revenue growth to drive earnings and dividend uplifts over the next two years. Revenues will benefit from the completion of three further development properties, currently under construction, which will add £2.3m to contracted rents.
1 Approximately 99% linked to the Retail Price Index (RPI) with the balance subject to fixed uplifts.
2 Collars represent the minimum level of annual rent uplift and caps the maximum, irrespective of the actual level of inflation.
Exhibit 3: Edison forecast growth in annualised contracted rent
£m |
FY24e |
FY25e |
FY26e |
Start-year annualised contracted rent roll |
56.6 |
60.4 |
64.4 |
Rent reviews |
2.1 |
1.8 |
1.6 |
Average uplift |
3.8% |
3.0% |
2.5% |
Acquisitions |
0.0 |
0.0 |
0.0 |
Disposals |
0.0 |
0.0 |
0.0 |
Development completions |
1.7 |
2.3 |
0.0 |
End-year annualised contracted rent roll |
60.4 |
64.4 |
66.0 |
Source: Edison Investment Research
We forecast continuing DPS growth
The dividend rebasing in mid-FY23 successfully established a level from which DPS could sustainably grow on a fully covered basis. We expect this to continue. Commencing in Q124, the quarterly rate of DPS was increased from 1.40p (the rebased level during H223) to 1.42p, although the total DPS for FY24, targeted by the company to be 5.712p, will be lower than the 6.180p declared for the whole of FY23. We forecast 2.2% growth in FY25 DPS and a further 2.0% in FY26, covered 1.07x and 1.05x by adjusted earnings, respectively. On an EPRA basis, dividend cover is much higher (1.32x in H124) due to the inclusion of non-cash IFRS rent smoothing adjustments.
Exhibit 4: Dividends paid/declared (reported to Q324 and Edison forecast thereafter)
DPS declared |
DPS paid |
||||||||
Pence per share |
FY23 |
FY24e |
FY25e |
FY26e |
FY23 |
FY24e |
FY25e |
FY26e |
|
Q1 |
1.690 |
1.428 |
1.46 |
1.49 |
1.690 |
1.400 |
1.428 |
1.46 |
|
Q2 |
1.690 |
1.428 |
1.46 |
1.49 |
1.690 |
1.428 |
1.46 |
1.49 |
|
Q3 |
1.400 |
1.428 |
1.46 |
1.49 |
1.690 |
1.428 |
1.46 |
1.49 |
|
Q4 |
1.400 |
1.428 |
1.46 |
1.49 |
1.400 |
1.428 |
1.46 |
1.49 |
|
Total |
6.180 |
5.712 |
5.840 |
5.960 |
6.470 |
5.684 |
5.808 |
5.930 |
|
Source: Target Healthcare REIT DPS data to Q324, Edison Investment Research forecasts for Q424 onwards.
Debt funding costs are substantially fixed
Of Target’s £320m of debt facilities, £259m was drawn at end-Q324, with an average term to maturity of 5.5 years. The drawn borrowing comprised £150m of long-term fixed-rate debt at a low average cost of 3.2%, with a first maturity in 2032, and £109m of shorter-term debt. The shorter-term debt is floating rate, but the interest costs on £80m of this have been capped at least until November 2025, and the blended interest cost is 4.4%. In aggregate, 89% of the Q324 drawn debt was fixed/hedged at an all-in rate, including the amortisation of loan arrangement costs, of 4.14%, with an average 5.5 years’ maturity. The £61m of undrawn borrowing would, if fully drawn, be at a variable interest cost of 2.22% plus SONIA. Allowing for undrawn debt, cash resources and £21m of investment commitments in respect of development funding, Target had £41m of available capital at end-Q324.
Exhibit 5: Summary of debt financing (as at end-Q324)
Lender |
Facility type |
Facility |
Drawn |
Term |
Margin |
Hedging |
Phoenix/Reassure |
Term loan |
£50m |
£50m |
Jan-32 |
Fixed 3.28% |
N/A |
Phoenix/Reassure |
Term loan |
£37m |
£37m |
Jan-32 |
Fixed 3.13% |
N/A |
Phoenix/Reassure |
Term loan |
£63m |
£63m |
Jan-37 |
Fixed 3.14% |
N/A |
RBS |
Term loan |
£50m |
£30m |
Nov-25 |
SONIA + 2.18% |
£30m swapped at 0.3% |
Revolving credit facility |
£20m |
Nov-25 |
SONIA + 2.33% |
|||
HSBC |
Revolving credit facility |
£100m |
£79m |
Nov-25 |
SONIA + 2.17% |
£50m capped at 3.0% |
Source: Target Healthcare REIT
Market interest rate expectations remain volatile, but currently anticipate a decline in the SONIA rate from c 5% currently to c 4% by November 2025. This indicates an increase in borrowing costs of shorter-term floating rate borrowings no later than the maturity in November 2025, corresponding with the expiry of the hedges. However, based on current market interest rates, we estimate that a good level of dividend cover would remain.
Our forecasts assume a refinancing with effect from July 2025 (the start of FY26), ahead of the November 2025 maturity, and we assume a debt margin of 2.5% over SONIA (forecast at 4.0% in FY26), or 6.5% in aggregate. On this basis, the increased DPS remains well-covered at 1.05x.
Portfolio yields have stabilised, supporting capital growth
Strong care sector fundamentals and non-cyclical, long-term, inflation-protected income prospects have mitigated the impact that rising bond yields and economic uncertainty have had on property valuations across the broad UK commercial property sector. Also, in contrast to that wider sector, investment demand for good-quality care home properties, especially modern, purpose-built properties with strong environmental credentials, has remained robust.
As a result, while the EPRA topped-up net initial yield (‘the valuation yield’) of Target’s portfolio rose in late 2022, directionally in line with the broader UK commercial property sector, the widening was significantly less, and valuations were more robust.
Over the past year, the yield on Target’s portfolio has stabilised, with a small tightening in Q324 to 6.19%. For the broad UK commercial property sector, yields have continued to widen. Driven by rental uplifts, during the first nine months of FY24, Target’s property valuation gains amount to c £4.4m compared with a loss of c £8.0m in the equivalent period of FY23. Our forecasts assume no change in yield, with rental growth continuing to generate valuation gains, supporting NAV growth. Our forecasts may prove to be conservative, given strong care home property sector fundamentals, the quality of Target’s assets and the market expectation of interest rate reductions. Target expects the valuation premium attached to better-quality care home real estate to increase further.
|
Exhibit 6: EPRA topped-up net initial yield |
|
|
Source: Target Healthcare REIT data |
Healthcare property is relatively defensive and characterised by lower volatility of returns compared with the broader commercial property sector, and Target’s portfolio has performed strongly versus the MSCI UK Annual Healthcare Property Index. In 2023 it was ranked first out of the 37 constituents, with an ungeared total property return of 9.7% versus 4.2% for the index. Target’s annualised total return since launch is 10.1% pa and over the more challenging past five years it is 8.0% pa (index: 5.9%).
Sustainable assets
At the core of its strategy, Target has an unwavering focus on high-quality, modern and sustainable assets, attractive to residents, operators and investors. Its investment thesis is that best-in-class properties in local areas with positive demand/supply characteristics and prevailing rental levels that are sustainable will always be attractive to existing or alternative tenants.
Key portfolio metrics include:
■
80% of its homes have been purpose-built from 2010 onwards.
■
99% of Target’s rooms benefit from full ensuite wet room provision, compared with 32% of total care home places in the UK, up from 14% in 2014. Capital expenditure projects are under way to increase portfolio wet room provision to 100%.
■
On average, homes provide 47sqm per resident including generous communal areas.
■
99% of the portfolio is EPC rated A or B and is compliant with the minimum energy efficiency standards anticipated to apply from 2030. 100% are rated C or better, already compliant with the minimum guidelines anticipated for 2027.
Tenants are performing well
The operator sector, in general, continues to benefit from the post-pandemic recovery in home occupancy, strong fee growth and an easing in staffing pressures. In combination this has provided an offset to inflationary cost pressures.
Based on the latest available data3 gathered from its tenants, underlying resident occupancy in Target’s mature homes4 remains on a slow but consistently upward trajectory, to around 87% currently. For the whole portfolio, end-December occupancy was 85%, prior to the two development completions in Q3. During the pandemic, occupancy reached a low of c 74% in April 2021 and there is further room for growth until it reaches the c 90% level that was typical before the pandemic. Target says that many operators have more recently been focused on admitting new residents at fee levels appropriate to the care package required, as opposed to prioritising occupancy in itself.
3 Data as of 31 December 2023
4 Homes that have had the same operator for a three-year period or more, and therefore excluding newly developed homes not yet stabilised.
Average weekly resident fees have continued to outstrip inflation and Target notes that fees for privately funded residents (two-thirds of the total across its tenants) have exceeded inflation over the past 25 years.
In addition to higher occupancy and strong fee growth, the caps on rent increases have also protected tenants against the pressures of elevated inflation, just as they are designed to do. Similarly, over previous periods of low inflation, the floors on rent increases (typically c 2%) have worked to the company’s advantage.
Rent cover5 for mature homes, now c 90%6 of the total, has continued to increase and was 1.90x in the December 2023 quarter compared with 1.5x in the prior year period. On a rolling 12-month basis, yet to fully reflect the continuing improvement, rent cover to end-December 2023 was 1.8x (12 months to December 2022: 1.4x).
5 Rent cover is a key measure of the underlying profitability of tenants and the sustainability of rents. The ratio tracks operational cash earnings at the home level (before rent), or EBITDARM, with the agreed rent.
6 Mature homes were 92% of the portfolio at end-H124 prior to the Q3 completion of the homes at Dartford and Holt.
On a quarterly (or spot) basis, rent cover is now above its pre-pandemic level, when resident occupancy was higher, and is also above the 1.6x that Target has previously indicated to be a realistic medium-term target for a typical home. Nonetheless, with room for resident occupancy to increase further, there seems every prospect of rent cover continuing to build.
|
Exhibit 7: Rent cover turning upwards |
Exhibit 8: Increasing share of homes at maturity |
|
|
|
Source: Target Healthcare REIT |
Source: Target Healthcare REIT |
|
Exhibit 7: Rent cover turning upwards |
|
|
Source: Target Healthcare REIT |
|
Exhibit 8: Increasing share of homes at maturity |
|
|
Source: Target Healthcare REIT |
Asset management initiatives and improved trading conditions restored rent collection to around 99% by end-FY23 (an average 97% for the year) and it has continued to be robust during the current year. During FY22, collection had dipped to around 95%, with a small number of tenants slow to recover from the pandemic.
In our forecasts we allow for 1% pa non-collection of rent, recognising that within a large portfolio of almost 100 homes spread across 32, mostly mid-sized, tenants, it is not unreasonable to expect some of these to face challenges from time to time.
Attractive dividend yield and discount to NAV
The targeted FY24 DPS of 5.712p represents a prospective yield of 7.0%, while the shares continue to trade at a discount of c 25% to Q324 NAV. Asset yields are above the property sector average, valuations appear well-supported, there is no material requirement for repair and maintenance capex, gearing is moderate and there is no ‘re-financing cliff’.
|
Exhibit 9: Dividend yield remains attractively high despite dividend rebasing |
Exhibit 10: P/NAV appears to discount material further property yield widening (valuation decline) |
|
|
|
Source: Target Healthcare REIT DPS data, LSEG prices |
Source: Target Healthcare REIT NAV per share data, LSEG prices |
|
Exhibit 9: Dividend yield remains attractively high despite dividend rebasing |
|
|
Source: Target Healthcare REIT DPS data, LSEG prices |
|
Exhibit 10: P/NAV appears to discount material further property yield widening (valuation decline) |
|
|
Source: Target Healthcare REIT NAV per share data, LSEG prices |
In Exhibit 11, we summarise the performance and valuation of a group of real estate investment trusts that we consider to be Target’s closest peers in the broad and diverse commercial property sector. The peer group is invested in the primary healthcare, supported housing and care home sectors, all targeting stable, long-term income growth derived from long lease exposures. For consistency, the data are presented on a trailing basis.
Exhibit 11: Peer valuation and performance summary
WAULT* |
Price |
Market cap (£m) |
P/NAV** |
Yield*** |
Share price performance |
||||
One month |
Three months |
One year |
Three years |
||||||
Assura |
11 |
43 |
1279 |
0.83 |
7.7 |
1% |
-4% |
-18% |
-43% |
Impact Healthcare |
21 |
89 |
367 |
0.77 |
7.7 |
1% |
4% |
-14% |
-24% |
Primary Health Properties |
11 |
96 |
1280 |
0.89 |
7.0 |
5% |
2% |
-11% |
-37% |
Residential Secure Income |
N/A |
47 |
87 |
0.59 |
11.0 |
-8% |
-3% |
-26% |
-50% |
Triple Point Social Housing |
25 |
61 |
240 |
0.54 |
9.0 |
2% |
3% |
33% |
-42% |
Average |
17 |
0.72 |
8.5 |
0% |
0% |
-7% |
-39% |
||
Target Healthcare |
26 |
82 |
508 |
0.75 |
6.9 |
0% |
-4% |
4% |
-32% |
UK property sector index |
1,370 |
3% |
2% |
-1% |
-24% |
||||
UK equity market index |
4,584 |
4% |
7% |
5% |
10% |
||||
Source: company data, LSEG pricing at 18 May 2024. Note: *Weighted average unexpired lease term. **Based on last reported NAV/NTA. ***Based on trailing 12-month DPS declared.
Appendix: Details of H124 financial performance
The H124 financial results were published on 12 March 2024. The earnings performance was robust, with increased rental income offsetting the impact of higher average borrowing costs in the period, mostly now fixed or hedged until November 2025. EPRA earnings and adjusted EPRA earnings were both at similar levels to H123 and H223. Property valuation gains versus losses in H123 generated a swing in IFRS earnings to a profit of £30.8m versus an H123 loss of £34.2m. NAV per share increased 2.1% in the six-month period to 106.7p, and including dividends paid the NAV total return was 4.8%. Borrowings increased modestly as debt was drawn to fund capex, but the net loan to value ratio of 25.8% remained conservative.
Exhibit 12: Summary of results for the six months to 31 December 2023 (H124)
£m unless stated otherwise |
H124 |
H123 |
H124/H123 |
H223 |
Cash rental income |
28.6 |
28.1 |
2% |
28.3 |
Other income |
0.0 |
0.1 |
0.0 |
|
Credit loss allowance |
(0.3) |
0.0 |
(0.3) |
|
Investment management fees |
(3.7) |
(3.8) |
-3% |
(3.6) |
Other expenses |
(1.5) |
(1.6) |
-6% |
(1.5) |
Finance expense |
(5.2) |
(4.6) |
14% |
(4.9) |
Development interest under forward fund agreements |
1.0 |
0.5 |
110% |
0.5 |
Adjusted earnings |
18.9 |
18.7 |
1% |
18.5 |
Development interest under forward fund agreements |
(1.0) |
(0.5) |
(0.5) |
|
Income from guaranteed rent reviews & lease incentives |
5.5 |
5.9 |
5.4 |
|
EPRA earnings |
23.4 |
24.1 |
-3% |
23.4 |
Realised/unrealised gains/(losses) on properties |
7.7 |
(58.0) |
4.6 |
|
Interest rate cap |
(0.4) |
(0.3) |
(0.4) |
|
Other income |
2.0 |
0.0 |
1.0 |
|
IFRS earnings |
30.8 |
(34.2) |
-190% |
27.6 |
IFRS EPS (p) |
4.96 |
-5.51 |
-190% |
4.45 |
EPRA EPS (p) |
3.78 |
3.89 |
-3% |
3.78 |
Adjusted EPS (p) |
3.05 |
3.01 |
1% |
2.99 |
DPS declared (p) |
2.86 |
3.38 |
-16% |
2.80 |
Dividend cover - EPRA earnings (x) |
0.00 |
0.00 |
0.00 |
|
Dividend cover - Adjusted earnings (x) |
1.07 |
0.89 |
1.07 |
|
EPRA NTA per share (‘NAV’ (p) |
106.7 |
103.0 |
104.5 |
|
EPRA NTA total return/accounting total return |
4.8% |
-5.2% |
4.4% |
|
Investment properties including investment via loans |
911.1 |
867.7 |
868.7 |
|
Borrowings |
252.5 |
240.0 |
230.0 |
|
Cash |
17.6 |
21.8 |
15.4 |
|
Gross LTV |
27.7% |
27.7% |
26.5% |
|
Net LTV |
25.8% |
25.1% |
24.7% |
Source: Target Healthcare REIT data, Edison Investment Research
Exhibit 13: Financial summary
Year to 30 June (£m) |
2022 |
2023 |
2024e |
2025e |
2026e |
||||
INCOME STATEMENT |
|||||||||
Rental income excluding guaranteed uplift |
48.8 |
56.4 |
58.2 |
62.2 |
64.6 |
||||
IFRS adjustment for guaranteed uplifts |
10.2 |
11.3 |
10.9 |
11.1 |
11.1 |
||||
Other income |
4.8 |
0.1 |
0.0 |
0.0 |
0.0 |
||||
Total revenue |
63.9 |
67.7 |
69.1 |
73.3 |
75.7 |
||||
Gains/(losses) on revaluation |
5.5 |
(53.4) |
19.1 |
13.0 |
13.3 |
||||
Realised gains/(losses) on disposal |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
||||
Management fee |
(7.3) |
(7.4) |
(7.4) |
(7.6) |
(7.9) |
||||
Credit loss allowance & bad debts |
(3.2) |
(0.3) |
(0.6) |
(0.6) |
(0.6) |
||||
Other expenses |
(3.2) |
(3.0) |
(3.1) |
(3.2) |
(3.3) |
||||
Operating profit |
55.7 |
3.6 |
77.1 |
74.8 |
77.2 |
||||
Net finance cost |
(6.6) |
(10.1) |
(11.8) |
(13.0) |
(14.2) |
||||
IFRS net result |
49.1 |
(6.6) |
65.3 |
61.8 |
63.0 |
||||
Adjust for: |
|||||||||
Gains/(losses) on revaluation |
(5.6) |
54.0 |
(19.1) |
(13.0) |
(13.3) |
||||
Other EPRA adjustments |
(3.9) |
0.1 |
0.8 |
0.8 |
0.4 |
||||
EPRA earnings |
39.7 |
47.6 |
47.1 |
49.6 |
50.1 |
||||
Adjust for fixed/guaranteed rent reviews |
(10.2) |
(11.3) |
(10.9) |
(11.1) |
(11.1) |
||||
Adjust for development interest under forward fund agreements |
0.8 |
1.0 |
1.6 |
0.3 |
0.0 |
||||
Group adjusted earnings |
30.2 |
37.2 |
37.8 |
38.7 |
39.0 |
||||
Average number of shares in issue (m) |
599.1 |
620.2 |
620.2 |
620.2 |
620.2 |
||||
IFRS EPS (p) |
8.20 |
(1.06) |
10.53 |
9.97 |
10.15 |
||||
EPRA EPS (p) |
6.6 |
7.7 |
7.6 |
8.0 |
8.1 |
||||
Adjusted EPS (p) |
5.0 |
6.0 |
6.1 |
6.2 |
6.3 |
||||
Dividend per share (declared) (p) |
6.76 |
6.18 |
5.71 |
5.84 |
5.96 |
||||
Dividend cover (EPRA earnings) (x) |
0.95 |
1.24 |
1.33 |
1.37 |
1.36 |
||||
Dividend cover (adjusted earnings) (x) |
0.72 |
0.97 |
1.07 |
1.07 |
1.05 |
||||
BALANCE SHEET |
|||||||||
Investment properties |
857.7 |
800.2 |
863.9 |
885.3 |
898.6 |
||||
Other non-current assets |
65.9 |
83.3 |
90.7 |
99.7 |
110.0 |
||||
Non-current assets |
923.6 |
883.4 |
954.6 |
985.0 |
1,008.6 |
||||
Cash and equivalents |
34.5 |
15.4 |
16.8 |
17.7 |
20.9 |
||||
Other current assets |
5.5 |
9.5 |
5.6 |
5.9 |
6.0 |
||||
Current assets |
40.0 |
24.8 |
22.4 |
23.6 |
26.9 |
||||
Bank loan |
(231.4) |
(227.1) |
(268.2) |
(273.8) |
(274.4) |
||||
Other non-current liabilities |
(7.1) |
(8.1) |
(8.5) |
(8.5) |
(8.5) |
||||
Non-current liabilities |
(238.5) |
(235.1) |
(276.7) |
(282.3) |
(282.9) |
||||
Trade and other payables |
(26.4) |
(18.3) |
(18.9) |
(20.1) |
(20.5) |
||||
Current Liabilities |
(26.4) |
(18.3) |
(18.9) |
(20.1) |
(20.5) |
||||
Net assets |
698.8 |
654.8 |
681.4 |
706.2 |
732.0 |
||||
Adjust for derivative financial liability |
(2.3) |
(6.9) |
(2.6) |
(0.8) |
0.0 |
||||
EPRA net tangible assets (NTA) |
696.5 |
647.9 |
678.8 |
705.4 |
732.0 |
||||
Period end shares (m) |
620.2 |
620.2 |
620.2 |
620.2 |
620.2 |
||||
IFRS NAV per share (p) |
112.7 |
105.6 |
109.9 |
113.9 |
118.0 |
||||
EPRA NTA per share (p) |
112.3 |
104.5 |
109.4 |
113.7 |
118.0 |
||||
EPRA NTA total return |
7.8% |
-1.2% |
10.2% |
9.2% |
9.0% |
||||
CASH FLOW |
|||||||||
Cash flow from operations |
35.6 |
40.8 |
47.6 |
51.6 |
53.1 |
||||
Premium paid for interest rate cap |
(2.6) |
0.0 |
0.0 |
0.0 |
|||||
Net interest paid |
(5.2) |
(8.6) |
(10.0) |
(11.6) |
(13.2) |
||||
Tax paid |
(0.0) |
0.0 |
0.0 |
0.0 |
0.0 |
||||
Net cash flow from operating activities |
30.4 |
29.7 |
37.6 |
40.0 |
39.9 |
||||
Purchase of investment properties |
(207.0) |
(29.3) |
(41.4) |
(8.1) |
0.0 |
||||
Disposal of investment properties |
4.4 |
25.8 |
0.0 |
0.0 |
0.0 |
||||
Net cash flow from investing activities |
(202.6) |
(3.6) |
(41.4) |
(8.1) |
0.0 |
||||
Issue of ordinary share capital (net of expenses) |
122.5 |
0.0 |
0.0 |
0.0 |
0.0 |
||||
(Repayment)/drawdown of loans |
104.8 |
(4.8) |
40.5 |
5.0 |
0.0 |
||||
Dividends paid |
(39.8) |
(40.3) |
(35.2) |
(36.0) |
(36.8) |
||||
Other |
(1.8) |
(0.2) |
0.0 |
0.0 |
0.0 |
||||
Net cash flow from financing activities |
185.6 |
(45.2) |
5.3 |
(31.0) |
(36.8) |
||||
Net change in cash and equivalents |
13.4 |
(19.1) |
1.5 |
0.9 |
3.1 |
||||
Opening cash and equivalents |
21.1 |
34.5 |
15.4 |
16.8 |
17.7 |
||||
Closing cash and equivalents |
34.5 |
15.4 |
16.8 |
17.7 |
20.9 |
||||
Balance sheet debt |
(231.4) |
(227.1) |
(268.2) |
(273.8) |
(274.4) |
||||
Unamortised loan arrangement costs |
(3.4) |
(2.9) |
(2.3) |
(1.7) |
(1.1) |
||||
Drawn debt |
(234.8) |
(230.0) |
(270.5) |
(275.5) |
(275.5) |
||||
Net cash/(debt) |
(200.3) |
(214.6) |
(253.7) |
(257.8) |
(254.6) |
||||
Gross LTV |
25.8% |
26.5% |
28.7% |
28.2% |
27.5% |
||||
Net LTV |
22.0% |
24.7% |
26.9% |
26.4% |
25.5% |
||||
Source: Target Healthcare REIT historical data, Edison Investment Research forecasts
|
|
Research: Consumer
Britvic’s interim results showcased a positive first half of FY24, with strong revenue growth across core brands and geographies. This was underpinned by a robust increase in volumes, reflecting product innovation and growth across its strategic pillars. Positive price/mix helped enable a 70bp improvement in margins. The enhanced profitability permitted a 16% increase in the interim dividend. Britvic continues to make strategic progress against the growth pillars of family favourite brands, Brazil and new growth areas. Management remains confident in the outlook, particularly with several key consumer activation events upcoming in the critical summer trading period. The company announced its third share buyback programme of up to £75m over the next 12 months.